ALRN Stock Overview
A biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Aileron Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.76 |
| 52 Week High | US$7.42 |
| 52 Week Low | US$1.61 |
| Beta | 2.34 |
| 11 Month Change | -22.69% |
| 3 Month Change | 10.40% |
| 1 Year Change | 48.39% |
| 33 Year Change | -79.45% |
| 5 Year Change | -70.14% |
| Change since IPO | -98.72% |
Recent News & Updates
Recent updates
Companies Like Aileron Therapeutics (NASDAQ:ALRN) Could Be Quite Risky
Aug 18
Is Aileron Therapeutics (NASDAQ:ALRN) In A Good Position To Deliver On Growth Plans?
Dec 30Aileron Therapeutics: An Assessment On A Lottery Ticket
Oct 21Aileron Therapeutics: Solving Chemotherapy's Toxicity
May 01Aileron Therapeutics +31% on insider buying more shares
Jan 08Aileron raises $40M via equity offering
Jan 06Aileron Therapeutics EPS in-line
Nov 13Shareholder Returns
| ALRN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -22.7% | -7.5% | -1.2% |
| 1Y | 48.4% | 14.1% | 30.4% |
Return vs Industry: ALRN exceeded the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: ALRN exceeded the US Market which returned 30.4% over the past year.
Price Volatility
| ALRN volatility | |
|---|---|
| ALRN Average Weekly Movement | 13.7% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ALRN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ALRN's weekly volatility has decreased from 22% to 14% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 15 | James Windsor | www.aileronrx.com |
Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company’s lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion.
Aileron Therapeutics, Inc. Fundamentals Summary
| ALRN fundamental statistics | |
|---|---|
| Market cap | US$61.10m |
| Earnings (TTM) | -US$29.24m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.0x
P/E RatioIs ALRN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALRN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$29.24m |
| Earnings | -US$29.24m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.35 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ALRN perform over the long term?
See historical performance and comparison